FR2602683B1 - Immunotoxines a longue duree d'action in vivo comportant une glycoproteine inhibant les ribosomes, modifiee par oxydation des motifs osidiques puis reduction - Google Patents

Immunotoxines a longue duree d'action in vivo comportant une glycoproteine inhibant les ribosomes, modifiee par oxydation des motifs osidiques puis reduction

Info

Publication number
FR2602683B1
FR2602683B1 FR8611644A FR8611644A FR2602683B1 FR 2602683 B1 FR2602683 B1 FR 2602683B1 FR 8611644 A FR8611644 A FR 8611644A FR 8611644 A FR8611644 A FR 8611644A FR 2602683 B1 FR2602683 B1 FR 2602683B1
Authority
FR
France
Prior art keywords
osid
oxidation
patterns
modified
reduction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR8611644A
Other languages
English (en)
Other versions
FR2602683A1 (fr
Inventor
Pierre Casellas
Bernard Bourrie
Xavier Canat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Priority to FR8611644A priority Critical patent/FR2602683B1/fr
Priority to IL80973A priority patent/IL80973A/xx
Priority to US06/941,989 priority patent/US4911912A/en
Priority to AT86402811T priority patent/ATE56977T1/de
Priority to ES86402811T priority patent/ES2018783B3/es
Priority to DE8686402811T priority patent/DE3674566D1/de
Priority to EP86402811A priority patent/EP0229564B1/fr
Priority to AU66629/86A priority patent/AU611848B2/en
Priority to PT83947A priority patent/PT83947B/pt
Priority to IE330686A priority patent/IE59650B1/en
Priority to DK611986A priority patent/DK611986A/da
Priority to KR1019860011020A priority patent/KR950007216B1/ko
Priority to JP61302888A priority patent/JPH0780903B2/ja
Publication of FR2602683A1 publication Critical patent/FR2602683A1/fr
Priority to US07/404,611 priority patent/US5106956A/en
Application granted granted Critical
Publication of FR2602683B1 publication Critical patent/FR2602683B1/fr
Priority to GR90401135T priority patent/GR3001236T3/el
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Toxicology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR8611644A 1985-12-20 1986-08-12 Immunotoxines a longue duree d'action in vivo comportant une glycoproteine inhibant les ribosomes, modifiee par oxydation des motifs osidiques puis reduction Expired - Fee Related FR2602683B1 (fr)

Priority Applications (15)

Application Number Priority Date Filing Date Title
FR8611644A FR2602683B1 (fr) 1986-08-12 1986-08-12 Immunotoxines a longue duree d'action in vivo comportant une glycoproteine inhibant les ribosomes, modifiee par oxydation des motifs osidiques puis reduction
IL80973A IL80973A (en) 1985-12-20 1986-12-15 Modified ribosome-inactivating glycoproteins,their preparation,immunotoxins containing them and pharmaceutical compositions containing such immunotoxins
US06/941,989 US4911912A (en) 1985-12-20 1986-12-15 Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and reduction, and in vivo prolonged-action immunotoxins containing such a glycoprotein
ES86402811T ES2018783B3 (es) 1985-12-20 1986-12-16 Glicoproteina modificada por oxidacion despues reduccion que inhibe los ribosomas, procedimiento de obtencion e inmunotoxinas que comportan tal glicoproteina.
DE8686402811T DE3674566D1 (de) 1985-12-20 1986-12-16 Mittels oxidierung und anschliessender reduzierung modifizierte, ribosome inhibierende glykoproteine, verfahren zur herstellung derselben und ein solches glykoprotein enthaltende immunotoxine.
EP86402811A EP0229564B1 (fr) 1985-12-20 1986-12-16 Glycoprotéines modifiées par oxydation puis réduction, inhibant les ribosomes, procédé d'obtention et immunotoxines comprenant une telle glycoprotéine
AT86402811T ATE56977T1 (de) 1985-12-20 1986-12-16 Mittels oxidierung und anschliessender reduzierung modifizierte, ribosome inhibierende glykoproteine, verfahren zur herstellung derselben und ein solches glykoprotein enthaltende immunotoxine.
PT83947A PT83947B (pt) 1985-12-20 1986-12-17 Processo para a obtencao de glicoproteinas inibidoras dos ribosomas, modificadas por oxidacao das funcoes osidicas seguido e reducao
AU66629/86A AU611848B2 (en) 1985-12-20 1986-12-17 Ribosome-inactivating glycoproteins, modified by oxydation of their osidic units and reduction, and in vivo prolonged- action immunotoxins containing such a glycoprotein
IE330686A IE59650B1 (en) 1985-12-20 1986-12-18 Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and reduction, and in vivo prolonged-action immunotoxins containing such a gylcoprotein
DK611986A DK611986A (da) 1985-12-20 1986-12-18 Riboson-inaktiverende glycoproteiner og immunotoksiner med forlaengetvirkning in vivo, der indeholder et saadant glycoprotein
KR1019860011020A KR950007216B1 (ko) 1985-12-20 1986-12-20 오시딕단위를 산화시키고, 환원시킴에 의해 리보솜을 비활성화시키는 당단백질을 변형시키는 방법
JP61302888A JPH0780903B2 (ja) 1985-12-20 1986-12-20 修飾糖タンパク質、当該修飾糖タンパク質の製造方法、当該修飾糖タンパク質を含む免疫毒素および当該免疫毒素を有効成分として含む抗ガン剤組成物
US07/404,611 US5106956A (en) 1985-12-20 1989-09-08 Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and reduction, and in vivo prolonged-action immunotoxins containing such a glycoprotein
GR90401135T GR3001236T3 (en) 1985-12-20 1990-12-21 Glycoproteins modified by oxidation followed by reduction, which inhibit ribosomes, production process and immunotoxines containing such a glycoprotein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8611644A FR2602683B1 (fr) 1986-08-12 1986-08-12 Immunotoxines a longue duree d'action in vivo comportant une glycoproteine inhibant les ribosomes, modifiee par oxydation des motifs osidiques puis reduction

Publications (2)

Publication Number Publication Date
FR2602683A1 FR2602683A1 (fr) 1988-02-19
FR2602683B1 true FR2602683B1 (fr) 1990-03-30

Family

ID=9338240

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8611644A Expired - Fee Related FR2602683B1 (fr) 1985-12-20 1986-08-12 Immunotoxines a longue duree d'action in vivo comportant une glycoproteine inhibant les ribosomes, modifiee par oxydation des motifs osidiques puis reduction

Country Status (1)

Country Link
FR (1) FR2602683B1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47372A (en) * 1975-05-27 1979-10-31 Yeda Res & Dev Fab'dimers bound to daunomycin or adriamycin,their preparation and pharmaceutical compositions containing same
JPS5843926A (ja) * 1981-09-08 1983-03-14 Suntory Ltd 選択性制癌剤

Also Published As

Publication number Publication date
FR2602683A1 (fr) 1988-02-19

Similar Documents

Publication Publication Date Title
IL134374A0 (en) Preparation of 3,3-dimethylbutyraldehyde by oxidation of 3,3-dimethylbutanol
NO11062A (no) Farmasöytisk sammensetning og matvaresupplement
PL338013A1 (en) Derivatives of condensed 1,2,4-thiadiazine, their production and application
DE3781786D1 (de) Prothese zum implantieren im hypodermgewebe des urogenitalbereichs.
PL335160A1 (en) Treatment of hiv and carcinoma
EP0263706A3 (en) Lactone modified, adducts or reactants and oleaginous compositions containing same
MX9203459A (es) Nuevos derivados de 2'-halometilideno, 2'-etenilideno y 2'-etinilcitidina, uridina y guanosina.
FR2602683B1 (fr) Immunotoxines a longue duree d'action in vivo comportant une glycoproteine inhibant les ribosomes, modifiee par oxydation des motifs osidiques puis reduction
DE3581210D1 (de) Immunotoxin und herstellung.
ZA894541B (en) Selective production of 2,6-diethylnaphthalene
FR2602682B1 (fr) Immunotoxines a longue duree d'action in vivo comportant une glycoproteine inhibant les ribosomes, modifiee par oxydation des motifs osidiques et formation d'une base de schiff
GB2203151B (en) 1,2,4-benzotriazine oxides as radiosensitisers and selective cytotoxic agents
GB8611650D0 (en) Personal deodorant
Mathis et al. Crohn's disease of the esophagus: dilation of stricture and fibrin sealing of fistulas
FR2591895B1 (fr) Immunotoxines a longue duree d'action in vivo comportant la chaine a de ricine modifiee sur ses motifs polysaccharidiques
FR2567164B1 (fr) Machine de detorsion et d'ouverture des tricots.
PL343758A1 (en) Purification of carboxaldehyde
FR2653996B1 (fr) Composition et solution aqueuse pour la repousse des cheveux.
DE69016196D1 (de) Propanolderivate und diese enthaltende Duftstoffe.
FR2591894B1 (fr) Immunotoxines a longue duree d'action in vivo comportant la chaine a de ricine modifiee sur ses motifs polysaccharidiques
OA09221A (fr) "Synthèse asymétrique des dérivés de la furo (3, 4-c) pyridine".
IT8823100A0 (it) Nuova sintesi della 2, 2'-a2-bis-ossazolina
PL304971A1 (en) Novel derivatives of n'-oxy-2,2'-bipyridilamine
IL119192A (en) Production of 2,3,5,6-tetrachloropyridine
IL119541A0 (en) Production of 2,3,5,6-tetrachloropyridine

Legal Events

Date Code Title Description
ST Notification of lapse